NCT02743611 2023-10-05Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal MelanomaBellicum PharmaceuticalsPhase 1/2 Terminated4 enrolled 9 charts